Ποια είναι η τιμή για Energenesis Biomedical CO.,LTD. (6657)

Η τιμή για Energenesis Biomedical CO.,LTD. (6657) είναι $0.97305026

Ποια είναι η κεφαλαιοποίηση αγοράς για Energenesis Biomedical CO.,LTD. (6657)

Η κεφαλαιοποίηση αγοράς για Energenesis Biomedical CO.,LTD. (6657) είναι $85.54M

Energenesis Biomedical CO.,LTD. (6657) Διαίρεση Μετοχών

Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.